OTLK News & Events

Latest data shows the largest indicative borrow rate increases among liquid option names include: Yellowstone Midco Holdings Ii, Llc (YSS) 18.35% +1.98, Vivopower Plc (VIVO) 15.14% +1.19, New Fortress Energy (NFE) 19.86% +0.95, Merlin Inc (MRLN) 38.55% +0.67, WhiteFiber Inc (WYFI) 9.26% +0.51, Starfighters Space, Inc. (FJET) 71.88% +0.39, GraniteShares 1.5x Long COIN Daily ETF (CONL) 11.23% +0.38, Outlook Therapeutics Inc (OTLK) 29.93% +0.35, Ocugen (OCGN) 1.23% +0.34, and BioSig Technologies Inc (STEX) 6.85% +0.32.

Outlook Therapeutics announced that it has entered into a definitive agreement providing for the purchase and sale of an aggregate of 8.54M shares of its common stock at a purchase price of 58.55c per share in a registered direct offering priced at-the-market under Nasdaq rules to GMS Ventures and Investments, the company's largest stockholder. The closing of the offering is expected to occur on or about May 29, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds to the company from the offering are expected to be $5M, before deducting offering expenses payable by the company. The company intends to use the net proceeds from this offering, together with existing cash and cash equivalents, for working capital and general corporate purposes. The company also has agreed to amend certain outstanding common stock warrants to purchase up to an aggregate of 15,488,570 shares of common stock previously issued to GMS Ventures and Investments in January 2025 and May 2025, with a weighted average exercise price of $1.78 per share, effective upon the closing of the offering, such that the amended warrants will have a reduced exercise price of 58.55c per share.

Outlook Therapeutics announced that it has entered into a definitive agreement providing for the purchase and sale of an aggregate of 8.54M shares of its common stock at a purchase price of 58.55c per share in a registered direct offering priced at-the-market under Nasdaq rules to GMS Ventures and Investments, the company's largest stockholder. The closing of the offering is expected to occur on or about May 29, subject to the satisfaction of customary closing conditions. The aggregate gross proceeds to the company from the offering are expected to be $5.0M, before deducting offering expenses payable by the company. The company intends to use the net proceeds from this offering, together with existing cash and cash equivalents, for working capital and general corporate purposes.

Outlook Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted the appeal following completion of the Formal Dispute Resolution, FDR, process with the Office of New Drugs, OND. The FDA concluded that substantial evidence of effectiveness has been established for Lytenava for the treatment of neovascular age-related macular degeneration, nAMD. As a result, Outlook Therapeutics expects to resubmit the ONS-5010/Lytenava Biologics License Application, BLA, in June 2026.